Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Arena Pharmaceuticals Announces Four Upcoming Presentations at the 2016 Advances in Inflammatory Bowel Diseases: Crohn's & Colitis Foundation's Clinical and Research Conference

Arena Pharmaceuticals
Posted on: 30 Nov 16

SAN DIEGO, Nov. 30, 2016 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that four abstracts will be presented at the 2016 Advances in Inflammatory Bowel Diseases: Crohn's & Colitis Foundation's Clinical and Research Conference on Friday, December 9 at 6:00pm ET.  The conference is taking place December 8-10 at the Walt Disney World Dolphin Hotel in Orlando, Florida.  The data will also be published in the February issue of the Inflammatory Bowel Diseases Journal, a peer-reviewed medical journal bringing the most current information in clinical and basic sciences to physicians caring for patients with inflammatory bowel diseases (IBD), and investigators performing research in IBD and related fields.

The following abstracts will be presented:

Title: Preclinical Safety Assessment of Etrasimod (APD334), an Oral Sphingosine-1-Phosphate Receptor (S1P) Modulator with a Unique Profile
Session Type: Poster Presentation
Poster Board Number:  P-250
Date: Friday, December 9 at 6:00pm-7:00pm ET
Location:  Exhibit Hall - Atlantic B-C

Title: The Sphingosine-1-Phosphate Receptor (S1P) Modulator Etrasimod (APD334) Demonstrates Limited Effects on Heart Rate in Preclinical Testing
Session Type: Poster Presentation
Poster Board Number: P-261
Date: Friday, December 9 at 6:00pm-7:00pm ET
Location:  Exhibit Hall - Atlantic B-C

Title: Safety, Pharmacokinetics and Pharmacodynamics of Etrasimod (APD334), an Oral Selective S1P Receptor Modulator, after Single Dose Escalation, in Healthy Volunteers
Session Type: Poster Presentation
Poster Board Number: P-179
Date: Friday, December 9 at 6:00pm-7:00pm ET
Location:  Exhibit Hall - Atlantic B-C

Title: Etrasimod (APD334), a Potent, Selective, Oral S1P Receptor Modulator With Autoimmune Disease-Modifying Activity that Exhibits Favorable PK/PD Properties in Healthy Volunteers
Session Type: Poster Presentation
Poster Board Number: P-180
Date: Friday, December 9 at 6:00pm-7:00pm ET
Location:  Exhibit Hall - Atlantic B-C

About Arena Pharmaceuticals
We are a biopharmaceutical company focused on developing novel, small molecule drugs across a range of therapeutic areas.  We have three primary proprietary investigational clinical programs: etrasimod (APD334) in Phase 2 evaluation for ulcerative colitis, APD371 entering Phase 2 evaluation for the treatment of pain associated with Crohn's disease, and ralinepag (APD811) in Phase 2 evaluation for pulmonary arterial hypertension (PAH).  Additionally, we have collaborations with the following pharmaceutical companies: Eisai Co., Ltd. and Eisai Inc. (commercial stage), Axovant Sciences Ltd. (Phase 2 candidate), and Boehringer Ingelheim International GmbH (preclinical candidate).

Our US operations are located in San Diego, California. Our primary clinical operations are located in Zug, Switzerland, and our commercial manufacturing for BELVIQ is located in Zofingen, Switzerland.

Forward-Looking Statements
Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the upcoming presentation; the publication of the data; and Arena's focus, primary programs and collaborations. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include those disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Contact: Arena Pharmaceuticals, Inc.                                                           
Kevin R. Lind, Chief Financial Officer                                 
klind@arenapharm.com                                                                     
858.210.3636

For more information:
www.arenapharm.com

Editor's Details

Mike Wood
PharmiWeb.com
www.pharmiweb.com
editor@pharmiweb.com

Last updated on: 30/11/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.